Tirzepatide
A once-weekly GIP and GLP-1 receptor agonist used under clinician-directed treatment plans.
At a glance
- ClassDual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
- ScheduleOnce weekly when prescribed. Use the same day each week according to the supplied instructions.
- ImportantCommercial products may be supplied as ready-to-use pens or vials and should not be reconstituted unless their instructions explicitly require it.
- Missed doseFollow the specific product instructions or contact the prescribing clinician.
10 mg vial reconstitution chart
The supplied sheet shows both 1 mL and 2 mL BAC-water options.
| Quantity | 1 mL: units | 1 mL: volume | 2 mL: units | 2 mL: volume |
|---|---|---|---|---|
| 0.5 mg | 5 | 0.05 mL | 2.5 | 0.025 mL |
| 1 mg | 10 | 0.10 mL | 5 | 0.05 mL |
| 2.5 mg | 25 | 0.25 mL | 12.5 | 0.125 mL |
| 5 mg | 50 | 0.50 mL | 25 | 0.25 mL |
| 7.5 mg | 75 | 0.75 mL | 37.5 | 0.375 mL |
| 10 mg | 100 | 1.00 mL | 50 | 0.50 mL |
Suggested dosing context
The supplied reference describes a once-weekly schedule using 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg steps. It suggests beginning at 2.5 mg and considering increases no more often than every four weeks based on tolerability and response.
| Stage | Suggested weekly quantity | Timing |
|---|---|---|
| Initial | 2.5 mg | Weeks 1-4 |
| Next step | 5 mg | Beginning week 5 |
| Later steps | 7.5-15 mg | 2.5 mg increments after at least 4 weeks |
- FrequencyOnce weekly, on the same day each week.
- AdministrationSubcutaneous administration, with abdomen, thigh, or back of the upper arm listed as example sites.
- ContinuationThe supplied material suggests basing restart or continuation decisions on the last well-tolerated quantity and time away.
- Upper referenceThe supplied reference identifies 10 mg as a commonly discussed maintenance level and says not to exceed 15 mg.
Suggested research combinations
The supplied reference lists retatrutide, semaglutide, cagrilintide, KLOW Blend, NAD+, MOTS-C, BPC-157, TB-500, GHK-Cu, KPV, SS-31, ipamorelin, and tesamorelin. This records the supplied material and is not a recommendation to combine therapies.
Important notes from the supplied sheet
- Described as a dual GIP/GLP-1 receptor agonist studied for metabolic health, appetite regulation, and weight management.
- Listed range: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg once weekly.
- Many users increase every four or more weeks based on tolerability and response.
- For restart or continuation, consider the last well-tolerated amount and time away.
- Use the same day and time each week.
- Store refrigerated at 2-8 C; discard 28-30 days after reconstitution or sooner if cloudy.
- Maintain hydration, nutrition, and resistance training.
- The supplied caution identifies 10 mg as a commonly studied maintenance amount and says not to exceed 15 mg.
Safety context
Tirzepatide can cause gastrointestinal adverse effects and has important contraindications, warnings, and drug-interaction considerations. A dosing table cannot replace screening, prescribing, and follow-up by a qualified clinician.